[go: up one dir, main page]

AU2001265839A1 - Use of potassium channel agonists for the treatment of cancer - Google Patents

Use of potassium channel agonists for the treatment of cancer

Info

Publication number
AU2001265839A1
AU2001265839A1 AU2001265839A AU6583901A AU2001265839A1 AU 2001265839 A1 AU2001265839 A1 AU 2001265839A1 AU 2001265839 A AU2001265839 A AU 2001265839A AU 6583901 A AU6583901 A AU 6583901A AU 2001265839 A1 AU2001265839 A1 AU 2001265839A1
Authority
AU
Australia
Prior art keywords
cancer
treatment
potassium channel
channel agonists
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265839A
Inventor
John Bondo Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2001265839A1 publication Critical patent/AU2001265839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001265839A 2000-06-26 2001-06-25 Use of potassium channel agonists for the treatment of cancer Abandoned AU2001265839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000987 2000-06-26
DKPA200000987 2000-06-26
PCT/DK2001/000442 WO2002000222A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2001265839A1 true AU2001265839A1 (en) 2002-01-08

Family

ID=8159577

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001265840A Abandoned AU2001265840A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for reducing fat food comsumption
AU2001265839A Abandoned AU2001265839A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001265840A Abandoned AU2001265840A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for reducing fat food comsumption

Country Status (3)

Country Link
US (2) US20020028808A1 (en)
AU (2) AU2001265840A1 (en)
WO (2) WO2002000222A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003239780A1 (en) * 2002-07-04 2004-01-23 Novo Nordisk A/S Polymorphic forms of a 4h-thieno(3,2-e)-1,2,4-thiadiazine 1,1-dioxide derivative
DE102004029909A1 (en) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Method and device for the preparation of bindable reagent carriers
US20060051418A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
WO2006091587A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of minoxidil sulfate as an anti-tumor drug
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
JP5543110B2 (en) 2006-01-05 2014-07-09 エッセンシャリス，インク． Potassium ATP channel opener salt and use thereof
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
WO2009099820A2 (en) * 2008-02-01 2009-08-13 Mayo Foundation For Medical Education And Research Modulating body weight
TWI383754B (en) * 2008-07-18 2013-02-01 Tci Co Ltd Food pastille
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF POTASSIUM ATP CHANNELS AND USES THEREOF
CN107106500B (en) 2014-11-14 2021-07-30 伊森舍丽斯有限公司 Methods for treating subjects with Prader-Willi syndrome or Smith-Magee syndrome
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (en) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH Geminal substituted aminobenzisoxazole compounds as agonists of 7-nicotinic acetylcholine receptors
CN106518804A (en) * 2016-07-31 2017-03-22 北京梅尔森医药技术开发有限公司 Novel crystal form of diazoxide and preparation method thereof
CA3049165A1 (en) * 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420780A (en) * 1972-03-22 1976-01-14 V N I Khim Farmatsevtichesky I Medicinal preparation of treatment of malignant neoplasms mostly hemoblastoses and chorionepithelioma
US5284845A (en) * 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
WO1997018332A1 (en) * 1995-11-13 1997-05-22 Brandeis University Regulation of cancer-causing tyrosine kinases by potassium ion conductance
IL125071A0 (en) * 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
CN1208418A (en) * 1996-01-17 1999-02-17 诺沃挪第克公司 Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, preparation method and use thereof
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
CA2294830A1 (en) * 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1999032494A1 (en) * 1997-12-19 1999-07-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
JP2000143539A (en) * 1998-11-05 2000-05-23 Hsp Kenkyusho:Kk Agent for suppressing expression of endoplasmic reticulum chaperone gene
WO2000033834A1 (en) * 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
ATE242254T1 (en) * 1998-12-18 2003-06-15 Novo Nordisk As CONDENSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
WO2002000223A1 (en) 2002-01-03
US20020035106A1 (en) 2002-03-21
WO2002000222A1 (en) 2002-01-03
AU2001265840A1 (en) 2002-01-08
US20020028808A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
AU2001265839A1 (en) Use of potassium channel agonists for the treatment of cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU2002249809A1 (en) Potassium channel inhibitors
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2001257325A1 (en) Cancer treatment
AU2002304883A1 (en) Device for the treatment of tumours
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2001265841A1 (en) Use of potassium channel openers for the treatment of insulitis
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2001266790A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 16, NO 12, PAGE(S) 2688-2711 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 45353/00, 78995/00, 56595/01, 65839/01, 65840/01, 66300/01, 13576/02